Literature DB >> 9817182

Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.

F J Meyer1, M Wencker, H Teschler, H Steveling, J Sennekamp, U Costabel, N Konietzko.   

Abstract

A 44 yr-old female with severe pulmonary emphysema and reduced alpha-1-protease inhibitor (alpha1-PI) serum levels developed an acute anaphylactic reaction following the third intravenous infusion of human alpha1-PI which was administered to prevent the progression of pulmonary emphysema. Specific immunoglobulin E-antibodies against human alpha1-PI could be demonstrated in the patient's serum using an enzyme allergosorbent test. Because of the risk of further severe anaphylactic reaction, the replacement therapy with alpha1-PI was discontinued. Physicians should be aware of this rare complication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817182     DOI: 10.1183/09031936.98.12040996

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  [Augmentation therapy with human alpha 1-protease inhibitor: whom to treat when?].

Authors:  M Wencker
Journal:  Med Klin (Munich)       Date:  1999-03-15

Review 2.  Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.

Authors:  Sanjay H Chotirmall; Mazen Al-Alawi; Thomas McEnery; Noel G McElvaney
Journal:  Ther Clin Risk Manag       Date:  2015-01-29       Impact factor: 2.423

Review 3.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

4.  Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.

Authors:  Irina Petrache; Joud Hajjar; Michael Campos
Journal:  Biologics       Date:  2009-07-13

Review 5.  Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.

Authors:  David G Parr; Beatriz Lara
Journal:  Drug Des Devel Ther       Date:  2017-07-14       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.